PRINCIPAL INVESTIGATOR

EXTERNAL POSTDOCTORAL COLLABORATORS:

• Javier Donate Correa. PhD in Biology. Postdoctoral Researcher. FIISC
• Víctor García Tagua. PhD in Molecular Biology and Biomedicine. Postdoctoral Researcher. FIISC

COLLABORATORS AND CLINICAL RESEARCHERS:

• Nayra Pérez Delgado (Clinical Analysis Service)
• Carolina Hernández Carballo (Internal Medicine)
• Sergio Rodríguez Ramos (Trasplant Coordination)
• Purificación Cerro (Trasplant Coordination)
• Ángel López Castillo (Vascular Surgery)
• Alejandro Delgado Molinos (Vascular Surgery)
• Victoria Castro (Pathological Anatomy)
• Carol Prieto Morín (Clinical Analysis)
• Orlando Siverio Morales (Nephrology)
• Desirée Luis Rodríguez (Nephrology)

PHD STUDENTS AND TRAINEES:

• Ernesto Martín Núñez (PFIS, Institute of Health Carlos III, FI14/00033)
• Carla María Ferri (The Canary Islands Agency of Research, Innovation and Information Sciences, ACIISI, TESIS2018010110)
• Víctor García Tagua (Stop Fuga de Cerebros («Stop Brain Drain») Fellowship. Roche Pharma – FIISC, C16/004)

RESEARCH LINES:

• Diabetic kidney disease.
• Chronic kidney disease and complications.
• Role of inflammation in high prevalence diseases.
• System FGF23/Klotho.

FUNDED PROJECTS:

• The FGF23/Klotho system as a predictor of cardiovascular morbidity and mortality (PI16/00024 – “Sistema FGF23/Klotho como predictor de morbi-mortalidad cardiovascular”). PI: Juan Francisco Navarro. Institute of Health Carlos III (2017-2019, 50,215 €).
• Kidney research Network (REDINREN, RD16/0009/0022 – “Red de Investigación Renal”). PI: Juan Francisco Navarro. Institute of Health Carlos III (2017-2021, 118,673.50 €).
• The FGF23/Klotho system in subclinical atherosclerotic vascular disease. Pathophysiological implications and therapeutic approach (PI19/00035 – «Sistema FGF23/Klotho en la enfermedad vascular aterosclerótica subclínica. Implicaciones fisiopatológicas y aproximación terapéutica). PI: Juan F. Navarro. Institute of Health Carlos III (2020-2022, 56,870 €).

PUBLICATIONS 2019:

• Fernandez-Fernandez B, Fernandez-Prado R,Górriz JL,Martinez-Castelao A, Navarro-González JF,Porrini E,Soler MJ,Ortiz A.Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J. 2019 May 31;12(3):313-321. doi: 10.1093/ckj/sfz070
• Heerspink HJL,Parving HH,Andress DL,Bakris G,Correa-Rotter R,Hou FF,KitzmanDW,Kohan D,Makino H,McMurray JJV,Melnick JZ,Miller MG,PergolaPE,Perkovic V,Tobe S, Yi T,Wigderson M,de Zeeuw D;SONAR Committees and Investigators (Navarro JF). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X
• Donate-Correa J,Martín-Núñez E,Hernández-Carballo C,Ferri C,TaguaVG, Delgado-Molinos A,López-Castillo Á,Rodríguez-Ramos S,Cerro-López P,López-Tarruella VC,Felipe-García R,Arévalo-Gomez MA,Pérez-Delgado N,Mora-Fernández C,Navarro-González JF.Fibroblast growth factor 23 expression in human calcified vascular tissues. Aging (Albany NY). 2019 Sep 22;11(18):7899-7913. doi: 10.18632/aging.102297
• Valls J,Cambray S,Pérez-Guallar C,Bozic M,Bermúdez-López M,Fernández E, Betriu À,Rodríguez I,Valdivielso JM, NEFRONA cohort (Navarro González JF). Association of candidate gene polymorphisms with chronic kidney disease: Results of a case-control analysis in the NEFRONA cohort. Front Genet. 2019 Feb 26;10:118. doi: 10.3389/fgene.2019.00118
• Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF. Inflammation in Diabetic Kidney Disease. Nephron. 2019;143(1):12-16. doi: 10.1159/000493278
• Donate-Correa J, García-Tagua V, Ferri CM, Martín-Núñez, E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF. Pentoxifylline for renal protection in diabetic kidney disease. A model of old drugs for new horizon J Clin Med. 2019 Feb 27;8(3). pii: E287. doi: 10.3390/jcm8030287
• Donate-Correa J, Martín-Núñez E, Ferri C, Hernández-Carballo C, García-Tagua V, Delgado-Molinos A, López-Castillo A, Rodríguez-Ramos S, Cerro-López P, Castro López-Tarruella V, Arévalo-González MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF. FGF23 and Klotho levels are independently associated with diabetic foot síndrome in type 2 diabetes mellitus. J Clin Med. 2019 Apr 3;8(4). pii: E448. doi: 10.3390/jcm8040448
• Martín-Núñez E, Donate-Correa J, Kannengiesser C, De Brauwere DP, Leroy C, Oudin C, Friedlander G, Prieto-Morín C, Tagua VG, Ureña-Torres PA, Navarro- González JF. A novel heterozygous deletion variant in KLOTHO gene leading to haploinsufficiency and impairment of fibroblast growth factor 23 signaling pathway. J Clin Med. 2019 Apr 12;8(4). pii: E500. doi: 10.3390/jcm8040500
• Valdivielso JM, Bozic M, Galimudi RK, Bermúdez-López M, Navarro-González JF, Fernández E, Betriu A, on behalf of the NEFRONA investigators. Association of the rs495392 Klotho polymorphism with atheromatosis progression in chronic kidney disease patients. Nephrol Dial Transplant. 2019 Dec 1;34(12):2079-2088. doi: 10.1093/ndt/gfy207

SELECTED PUBLICATIONS FROM THE LAST 10 YEARS:

• Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C. Effects of pentoxifylline on soluble Klotho concentrations and renal tubular cell expression in diabetic kidney disease. Diabetes Care. 2018 Aug;41(8):1817-1820. doi:10.2337/dc18-0078
• Donate-Correa J, Henriquez-Palop F, Martín-Núñez E, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernandez C, Navarro-González JF. Effect of Paricalcitol on FGF-23 and Klotho in kidney transplant recipients. 2016;100(11):2432-2438. doi: 10.1097/TP.0000000000001339
• Donate-Correa J, Martín-Núñez E, Perez Delgado N, Muros de Fuentes M, Ortiz Arduan A, Mora-Fernandez C, Navarro-Gonzalez JF. Implications of fibroblast growth factor/Klotho system in glucose metabolism and diabetes. Cytokine Growth Factor Rev. 2016 Apr;28:71-7. doi: 10.1016/j.cytogfr.2015.12.003
• Donate-Correa J, Martín-Núñez E, Martinez-Sanz R, Muros de Fuentes M, Mora-Fernandez C, Pérez-Delgado N, Navarro-González JF. Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease. J Cell Mol Med. 2016 Jan;20(1):128-33. doi: 10.1111/jcmm.12710
• Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P, Jarque A, García J. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol. 2015 Jan;26(1):220-9. doi: 10.1681/ASN.2014010012